Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haihe Biopharma PARP1 compound 30
- Development stage
- Unknown
- Lead developer
- Haihe
01
Overview
Haihe Biopharma PARP1 compound 30: sourced facts only. name: "Herein, we report the discovery of pyrazolo[1,5,4-de]quinoxalin-2(3H)-one 30 as a novel selective PARP1 inhibitor." [PMID:39571073]; target: "Herein, we report the discovery of pyrazolo[1,5,4-de]quinoxalin-2(3H)-one 30 as a novel selective PARP1 inhibitor." [PMID:39571073]; developer: "Discovery & Early Development, Haihe Biopharma Co., Ltd, Shanghai 201203, China." [PMID:39571073]; stage: "30 achieved tumor regression in the BRCA1-mutated MDA-MB-436 xenograft model and showed synergistic efficacy in combination with carboplatin in the SUM149PT xenograft model." [PMID:39571073]
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on Haihe Biopharma PARP1 compound 30.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haihe Biopharma PARP1 compound 30.